+123 456 7890 1600 Amphitheatre Parkway Mountain View, CA 94043

Review highlights potential of cancer immunotherapy plus targeted therapy

“To support this goal and accelerate these efforts, changes in directions of research support and funding may be required,” co-authors Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology and Immunology, and Jim Allison, Ph.D., chair of Immunology, said in the review. The review, titled “Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential,” covers the strengths and weaknesses of the two forms of therapy and notes how their combination could be particularly potent. …

Read More »

Ebola whole virus vaccine shown effective, safe in primates

The vaccine, described today (March 26, 2015) in the journal Science, was developed by a group led by Yoshihiro Kawaoka, a University of Wisconsin-Madison expert on avian influenza, Ebola and other viruses of medical importance. It differs from other Ebola vaccines because as an inactivated whole virus vaccine, it primes the host immune system with the full complement of Ebola viral proteins and genes, potentially conferring greater protection. “In terms of efficacy, this affords excellent protection,” explains Kawaoka, a professor of pathobiological sciences in the UW-Madison School of Veterinary Medicine and who also holds a faculty appointment at the University of Tokyo…

Read More »

Scientists pioneer new drug regimen that reduces toxicities for renal cancer patients

The seven-year study began in 2007 and the findings revolutionized the standard protocol for patient management in NCCS with an attenuated-dose regimen of sunitinib for patients with mRCC. The new treatment regimen for sunitinib has been accepted by oncologists in Singapore. For the patients, this would mean an estimated 30 per cent reduction in fees because of the lower dosage. …

Read More »

Naproxen plus acid blocking drug shows promise in preventing bladder cancer

A new study suggests there may be ways to reduce these dangerous side effects. Collaborators from the University of Michigan, the National Cancer Institute and the University of Alabama looked at naproxen, which is known to have a lower cardiovascular risk than other NSAIDs. Naproxen, like most NSAIDs and aspirin, does increase the risk for gastric ulcers or bleeding…

Read More »

Concurrent chemoradiation treatment at high-volume facilities improves survival for NSCLC

Lung cancer is the leading cause of cancer related death in the US with 159,000 deaths and 224,000 diagnoses each year, with NSCLC accounting for 85% of the cases. The stage of lung cancer is determined based on the size of the tumor, the extent and location of lymph node involvement, and whether or not the tumor has metastasized to distant regions. Approximately one quarter of NSCLC cases are diagnosed at stage III, with only 25% of those patients surviving at least 5 years. …

Read More »

Global health experts call into question sub-Saharan cancer data

Cancer data compiled by the World Health Organisation’s (WHO) GLOBOCAN project has huge global influence and is used by Governments and international NGOs to determine health and funding priorities in sub-Saharan Africa. However, no independent evaluation of the data has ever been undertaken. For the first time, experts from Queen Mary University of London have critically evaluated all publically available information on the quality of cancer registration systems in sub-Saharan Africa. …

Read More »

national